Cytosorbents (CTSO) Invested Capital (2011 - 2026)

Cytosorbents (CTSO) has reported Invested Capital for 15 consecutive years, with $16.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Invested Capital fell 36.49% year-over-year to $16.5 million; the trailing twelve-month figure through Jun 2026 stood at $16.5 million (down 36.49% YoY), and the FY2025 full-year result was $22.6 million, down 10.09% from the prior year.
• Invested Capital eased to $16.5 million in Q2 2026 per CTSO's latest filing, from $19.2 million in the prior quarter.
• Across five years, Invested Capital topped out at $40.4 million in Q4 2022 and bottomed at $16.5 million in Q2 2026.
• Historically, Invested Capital has averaged $26.8 million across 5 years, with a median of $26.0 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Invested Capital grew 19.44% in 2025, then sank 36.49% in 2026.
• Over 5 years, Invested Capital stood at $40.4 million in 2022, then slipped by 29.36% to $28.5 million in 2023, then retreated by 11.99% to $25.1 million in 2024, then dropped by 10.09% to $22.6 million in 2025, then fell by 26.94% to $16.5 million in 2026.
• According to Business Quant data, Invested Capital over the past three periods registered $16.5 million, $19.2 million, and $22.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.